Abstract
Effectiveness of cancer therapy is improved by the use of recombinant immunotoxins (RITs) that target membrane proteins unique to malignant tumor cells. Although RIT antitumor activity in vivo can always be improved with larger doses, clinical restriction on the dose toleration makes it critical to explore how RIT antitumor activity can be maximized without resorting to dose elevation. In this work, a mathematical model was developed to explore functional correlations between the properties of several recombinant immunotoxins and their antitumor efficacies in vivo. Simulations were compared with experimental data of human tumor xenografts grown on nude mice to assess parameters critical to optimal antitumor activity. We dissected out or held constant as many parameters of the model as possible to investigate the effect of the remaining parameters on the behavior of the system as a whole. Empirical correlations between immunotoxin binding affinity and the target binding site density were obtained for several recombinant immunotoxins targeting either human A431 carcinoma or CD46 Burkitt’s lymphoma. Simulations reinforced the idea of binding site barrier for drug diffusion and suggested that optimal antitumor activity was achieved when the binding affinity is logarithmically dependent on the target binding site density.
Similar content being viewed by others
Abbreviations
- Mab:
-
Monoclonal antibody
- IT:
-
Immunotoxin
- RIT:
-
Recombinant immunotoxin
- PE:
-
Pseudomonas exotoxin
- RSC:
-
Relative sensitivity coefficient
- ECS:
-
Extracellular space
- IL2Rα:
-
Interleukin-2 receptor α-subunit
- ER:
-
Endoplasmic reticulum
- ADP:
-
Adenosine diphosphate
- PEG:
-
Polyethylene glycol
- GPI:
-
Glycophosphatidylinositol
References
Adams G. P., Schier R., McCall A. M., Simmons H. H., Horak E. M., Alpaugh R. K., Marks J. D., Weiner L. M. (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61:4750–4755
Bang S., Nagata S., Onda M., Kreitman R. J., Pastan I. (2005) HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin. Cancer Res. 11:1545–1550
Benhar I., Pastan I. (1995) Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3. J. Biol. Chem. 270:23373–23380
Bera T. K., Onda M., Brinkmann U., Pastan I. (1998) A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2. J. Mol. Biol. 281:475–483
Bera T. K., Viner J., Brinkmann E., Pastan I. (1999) Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Cancer Res. 59:4018–4022
Bera T. K., Williams-Gould J., Beers R., Chowdhury P., Pastan I. (2001) Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer. Mol. Cancer Ther. 1:79–84
Bigner D. D., Archer G. E., McLendon R. E., Friedman H. S., Fuchs H. E., Pai L. H., Herndon J. E., Pastan I. (1995) Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. Clin. Cancer Res. 1:1545–1555
Breward C. J. W., Byrne H. M., Lewis C. E. (2001) Modeling the interactions between tumor cells and a blood vessel in a microenvironment within a vascular tumor. Eur. J. Appl. Math. 12:529–556
Brinkmann U., Pai L. H., FitzGerald D. J., Willingham M., Pastan I. (1991) B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. USA 88:8616–8620
Brinkmann U., Pastan I. (1995) Recombinant immunotoxins: from basic research to cancer therapy. Methods 8:143–156
Bruehlmeier M., Roelcke U., Blauenstein P., Missimer J., Schubiger P. A., Locher J. T., Pellikka R., Ametamey S. M. (2003) Measurement of the extracellular space in brain tumors using 76Br-bromide and PET. J. Nucl. Med. 44:1210–1218
Chan C. H. T., Wang J., French R. R., Glennie M. J. (1998) Internalization of the lymphocytic surface protein CD22 is controlled by a novel membrane proximal cytoplasmic motif. J. Biol. Chem. 273: 27809–27815
Chang M. P., Bramhall J., Graves S., Bonavida B., Wisnieski B. J. (1989) Internucleosomal DNA cleavage proceeds diphtheria toxin-induced cytolysis: evidence that cell lysis is not a simple consequence of translation inhibition. J. Biol. Chem. 264:15261–15267
Chang K., Pai L. H., Bera J. K., Pastan I., Willingham M. C. (1992) Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res. 52:181–186
Chowdhury P. S., Pastan I. (1999) Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol. 17:568–572
Chowdhury P. S., Viner J. L., Beers R., Pastan I. (1998) Isolation of a high-affinity stable single chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc. Natl. Acad. Sci. USA 95:669–674
Dean G. S., Pusztai L., Xu F. J., O’Briant K., DeSombre K., Conaway M., Boyer C. M., Mendelsohn J., Bast R. C. Jr (1998) Cell surface density of p185c-erbB-2determines susceptibility to anti-p185c-erbB-2-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170EGFR-RTA in ovarian cancer cells. Clin. Cancer Res. 4:2545–2550
Filho I. P. T., Leunig M., Yuan F., Intaglietta M., Jain R. K. (1994) Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. Proc. Natl. Acad. Sci. USA 91:2081–2085
Graff C. P., Wittrup K. D. (2003) Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 63:1288–1296
Hassan R., Chuanchu W., Brechbiel M. W., Margylies I., Kreitman R. J., Pastan I. (1999) 111Indium-labeled monoclonal antibody K1: biodisitribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. Int. J. Cancer 80:559–563
Hessler J. L., Kreitman R. J. (1997) An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry 36:14577–14582
Hudson T. H., Neville D. M. Jr (1987) Temporal separation of protein toxin translocation from processing events. J. Biol. Chem. 262:16484–16494
Jackson T. L. (2002) Vascular tumor growth and treatment: consequences of polyclonality, competition and dynamic vascular support. J. Math. Biol. 44:201–226
Jackson T. L. (2003) Intracellular accumulation and mechanism of action of doxorubicin in a spatio-temporal tumor model. J. Theor. Biol. 220:201–213
Jain R. K. (2001) Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46:149–168
Juweid M., Neumann R., Paik C., Perez-Bacete M. J., Sato J., Van Osdol W., Weinstein J. N. (1992) Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 52:5144–5153
Kirpotin D., Park J. W., Hong K., Zalipsky S., Li W.-L., Carter P., Benz C. C., Papahadjopoulos D. (1997) Sterically stabilized anti-Her2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36:66–75
Kobayashi H., Kao C.-H., Kreitman R. J., Le N., Kim M.-K., Brechbiel M. W., Paik C. H., Pastan I., Carrasquillo J. A. (2000) Pharmacokinetics of 111In- and 125I-labeled anti-Tac single-chain Fv recombinant immunotoxin. J. Nucl. Med. 41:755–762
Kochi S. K., Collier R. J. (1993) DNA fragmentation and cytolysis in U937 cells treated with diphtheria toxin or other inhibitors of protein synthesis. Exp. Cell Res. 208:296–302
Kreitman R. J., Bailon P., Chaudahry V. K., FitzGerald D. J., Pastan I. (1994) Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expression human carcinoma. Blood 83:426–434
Kreitman R. J., Margulies I., Stetler-Stevenson M., Wang Q.-C., FitzGerald D. J. P., Pastan I. (2000) Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin. Cancer Res. 6:1476–1487
Kreitman R. J., Pastan I. (1998) Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res. 58:968–975
Kreitman R. J., Wang Q.-C., FitzGerald D. J., Pastan I. (1999) Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int. J. Cancer 81:148–155
Krupp M. N., Connolly D. T., Lane M. D. (1982) Synthesis, turnover, and down-regulation of epidermal growth factor receptors in human A431 epidermoid carcinoma cells and skin fibroblasts. J. Biol. Chem. 257:11489–11496
Mansfield E., Amlot P., Pastan I., FitzGerald D. J. (1997) Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood 90:2020–2026
Moynihan M. R., Pappenheimer A. M. (1981) Kinetics of adenosinediphosphoribosylation of elongation factor 2 in cells exposed to diphtheria toxin. Infect. Immun. 32:575–582
Olsnes S., Sandvig K., Refsnes K., Pihl A. (1976) Rates of different steps involved in the inhibition of protein synthesis by the toxic lectins brin and ricin. J. Biol. Chem. 257:3985–3992
Onda M., Kreitman R. J., Vasmatzis G., Lee B., Pastan I. (1999) Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J. Immunol. 163:6072–6077
Onda M., Nagata S., Tsutsumi Y., Vincent J. J., Wang Q.-C., Kreitman R. J., Lee B., Pastan I. (2001) Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting anti-tumor activity. Cancer Res. 61:5070–5077
Pai L. H., Janendra K. B., FitzGerald D. J., Willingham M. C., Pastan I. (1991) Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA 88:3358–3362
Press W. H., Teukolsky S. A., Vetterling W. T., Flannery B. P. (1996) Numerical Recipes in Fortran 90. 2nd Edition. Cambridge University Press, New York
Reiter Y., Brinkmann U., Jung S.-H., Lee B., Kasprzyk P. G., King C. R., Pastan I. (1994) Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J. Biol. Chem. 269:18327–18331
Reiter Y., Brinkmann U., Kreitman R. J., Jung S.-H., Lee B. K., Pastan I. (1994) Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochem. 33:5451–5459
Reiter Y., Kreitman R. J., Brinkmann U., Pastan I. (1994) Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. Int. J. Cancer 58:142–149
Reiter Y., Pai L. H., Brinkmann U., Wang Q.-C., Pastan I. (1994) Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res. 54:2714–2718
Reiter Y., Pastan I. (1998) Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol. 16:513–520
Rippley R. K., Stokes C. L. (1995) Effects of cellular pharmacology on drug distribution in tissues. Biophys. J. 69:825–839
Rönnberg B. J., Middlebrook J. L. (1989) Cellular regulation of diphtheria toxin cell surface receptors. Toxicon 27:1377–1388
Salvatore G., Beers R., Margulies I., Kreitman R. J., Pastan I. (2002) Improved cytotoxicity activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin. Cancer Res. 8:995–1002
Skretting G., Torgersen M. L., Van Deurs B., Sandvig K. (1999) Endocytosis mechanisms responsible for GPI-linked diphtheria toxin receptor. J. Cell Sci. 112:3899–3909
Sung C., Shockley T. R., Morrison P. F., Dvorak H. F., Yarmush M. L., Dedrick R. L. (1992) Predicted and observed effects of antibody and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res. 52:377–384
Tsutsumi Y., Onda M., Nagata S., Lee B., Kreitman R. J., Pastan I. (2000) Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. USA 97:8548–8553
Uchida T., Pappenheimer A. M., Harper A. A. (1973) Diphtheria toxin and related proteins. II. Kinetic studies on intoxication of Hela cells by diphtheria toxin and related proteins. J. Biol. Chem. 248:3845–3850
Van Horssen P. J., Van Oosterhout Y. V., De Witte T., Preijers F. W. (1995) Cytotoxic potency of CD22-ricin A depends on intracellular routing rather than on the number of internalized molecules. Scand. J. Immunol. 41:563–569
Vargova L., Homola A., Zamecnik J., Tichy M., Benes V., Sykova E. (2003) Diffusion parameters of the extracellular space in human gliomas. Glia 42:77–88
Vincensini D., Dedieu V., Eliat P. A., Vincent C., Bailly C., de Certaines J., Joffre F. (2007) Magnetic resonance imaging measurements of vascular permeability and extracellular volume fraction of breast tumors by dynamic Gd-DTPA-enhanced relaxometry. Magn. Reson. Imaging 25: 293–302
Weinstein J. N., VanOsdol W. (1992) Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the “binding site barrier”. Cancer Res. 52:2747s–2751s
Wenning L. A., Murphy R. M. (1999) Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids. Biotechnol. Bioeng. 62:562–575
Yuan F., Leunig M., Berk D. A., Jain R. K. (1993) Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. Microvasc. Res. 45:269–289
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, K.C., Kim, J., Li, X. et al. Modeling Recombinant Immunotoxin Efficacies in Solid Tumors. Ann Biomed Eng 36, 486–512 (2008). https://doi.org/10.1007/s10439-007-9425-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10439-007-9425-4